CYTK (Cytokinetics Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by CYTK officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-22 | Fady Ibraham Malik | EVP Research & Development | MIXED | — | — |
| 2026-09-15 | Robert E Landry | Director | Sell | — | — |
| 2026-09-15 | Robert I Blum | President & CEO | MIXED | — | — |
| 2026-09-11 | Robert E Landry | Director | Sell | — | — |
| 2026-09-08 | Fady Ibraham Malik | EVP Research & Development | MIXED | — | — |
| 2026-09-01 | B LYNNE PARSHALL | Director | Sell | — | — |
| 2026-08-31 | Robert I Blum | President & CEO | MIXED | — | — |
| 2026-08-31 | Andrew Callos | EVP, Chief Commercial Officer | MIXED | — | — |
| 2026-08-18 | Fady Ibraham Malik | EVP Research & Development | MIXED | — | — |
| 2026-08-10 | Robert I Blum | President & CEO | MIXED | — | — |
| 2026-07-30 | Andrew Callos | EVP, Chief Commercial Officer | MIXED | — | — |
| 2026-07-27 | Robert I Blum | President & CEO | MIXED | — | — |
| 2026-07-23 | Fady Ibraham Malik | EVP Research & Development | MIXED | — | — |
| 2026-07-16 | James M Daly | Director | A | — | — |
| 2026-07-16 | Edward M. MD Kaye | Director | A | — | — |
| 2026-07-16 | WENDELL WIERENGA | Director | A | — | — |
| 2026-07-16 | JOHN T HENDERSON | Director | A | — | — |
| 2026-07-16 | Robert Arthur Harrington | Director | A | — | — |
| 2026-07-16 | Nancy Wysenski | Director | A | — | — |
| 2026-07-14 | Robert I Blum | President & CEO | MIXED | — | — |
| 2026-07-07 | Fady Ibraham Malik | EVP Research & Development | MIXED | — | — |
| 2026-07-02 | Robert I Blum | President & CEO | Sell | — | — |
| 2026-07-02 | Sung Lee | EVP, Chief Financial Officer | MIXED | — | — |
| 2026-07-02 | Andrew Callos | EVP, Chief Commercial Officer | MIXED | — | — |
| 2026-06-29 | Sung Lee | EVP, Chief Financial Officer | MIXED | — | — |
| 2026-06-29 | Sung Lee | EVP, Chief Financial Officer | MIXED | — | — |
| 2026-06-23 | Fady Ibraham Malik | EVP Research & Development | MIXED | — | — |
| 2026-06-15 | Robert I Blum | President & CEO | Sell | — | — |
| 2026-06-09 | Fady Ibraham Malik | EVP Research & Development | MIXED | — | — |
| 2026-06-01 | B LYNNE PARSHALL | Director | Sell | — | — |
| 2026-06-01 | Andrew Callos | EVP, Chief Commercial Officer | MIXED | — | — |
| 2026-06-01 | Edward M. MD Kaye | Director | Sell | — | — |
| 2026-05-28 | Robert I Blum | President & CEO | Sell | — | — |
| 2026-05-27 | Nancy Wysenski | Director | A | — | — |
| 2026-05-27 | WENDELL WIERENGA | Director | A | — | — |
| 2026-05-27 | Robert E Landry | Director | A | — | — |
| 2026-05-27 | B LYNNE PARSHALL | Director | A | — | — |
| 2026-05-27 | Edward M. MD Kaye | Director | A | — | — |
| 2026-05-27 | JOHN T HENDERSON | Director | A | — | — |
| 2026-05-27 | Robert Arthur Harrington | Director | A | — | — |
| 2026-05-27 | James M Daly | Director | A | — | — |
| 2026-05-27 | Muna Bhanji | Director | A | — | — |
| 2026-05-20 | Fady Ibraham Malik | EVP Research & Development | MIXED | — | — |
| 2026-05-14 | Robert I Blum | President & CEO | Sell | — | — |
| 2026-05-05 | Andrew Callos | EVP, Chief Commercial Officer | MIXED | — | — |
| 2026-05-05 | JOHN T HENDERSON | Director | MIXED | — | — |
| 2026-05-05 | Sung Lee | EVP, Chief Financial Officer | Sell | — | — |
| 2026-05-05 | WENDELL WIERENGA | Director | MIXED | — | — |
| 2026-05-05 | Fady Ibraham Malik | EVP Research & Development | MIXED | — | — |
| 2026-05-04 | Andrew Callos | EVP, Chief Commercial Officer | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 2,883,845 | — |
| — | — | 2,811,818 | — |
| — | — | 2,777,320 | — |
| — | — | 2,760,185 | — |
| — | — | 2,350,829 | — |
| — | Director | 723,487 | — |
| — | President & CEO | 475,746 | — |
| — | EVP Research & Development | 157,402 | — |
| — | Chief HR & Admin Officer | 153,233 | — |
| — | Chief Legal & Admin Officer | 107,943 | — |
| — | SVP - Legal & General Counsel | 103,408 | — |
| — | SVP Finance & CFO | 87,346 | — |
| — | Director | 78,443 | — |
| — | EVP, Chief Financial Officer | 64,333 | — |
| — | EVP, Chief Commercial Officer | 58,555 | — |
| — | SVP & CMO | 47,255 | — |
| — | SVP Drug Discovery & Early Dev | 46,441 | — |
| — | EVP, Finance & CFO | 40,323 | — |
| — | Director | 35,563 | — |
| — | Director | 33,992 | — |
| — | EVP, Chief Legal Officer | 33,140 | — |
| — | GC & Chief Compliance Officer | 32,548 | — |
| — | Director | 32,345 | — |
| — | Director | 30,782 | — |
| — | Director | 30,100 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CYTK quote page; the site-wide leaderboard is on the insider transactions hub.